New drug combo shows promise for tough liver cancer
NCT ID NCT04301778
First seen Mar 15, 2026 · Last updated May 22, 2026 · Updated 14 times
Summary
This study tested a combination of two drugs (durvalumab and SNDX-6352) in 5 adults with a rare liver cancer that could not be surgically removed. The goal was to see if the treatment was safe and could shrink tumors after standard liver-directed therapy. The trial is complete, and results focused on tumor response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.